Get the Stockscreener App
6.81
0.87%
-0.06
Prothena Corporation Plc stock is traded at $6.81, with a volume of 840.78K.
It is down -0.87% in the last 24 hours and up +8.79% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$6.87
Open:
$6.8
24h Volume:
840.78K
Relative Volume:
0.49
Market Cap:
$366.56M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-6.81
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+1.95%
1M Performance:
+8.79%
6M Performance:
-52.14%
1Y Performance:
-69.48%
1-Day Range:
$6.61
$6.87
1-Week Range:
$6.61
$7.33
52-Week Range:
$4.32
$23.66
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
6.81 | 369.79M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Key resistance and support levels for Prothena Corporation plcRisk-Managed Strategy Based on Price Analysis - Newser
Ranking Prothena Corporation plc among high performing stocks via toolsValue Investing Summary and Earnings Outlook - Newser
How volatile is Prothena Corporation plc stock compared to the marketEntry Signal Planner To Watch Now - jammulinksnews.com
Intraday pattern recognizer results for Prothena Corporation plcFree Fast Entry High Potential Stock Alerts - Newser
Volume spikes in Prothena Corporation plc stock – what they meanWeekly Breakout Forecast with Entry Zones - Newser
How many analysts rate Prothena Corporation plc as a “Buy”Pre Market Recommendation With Low Risk - jammulinksnews.com
Can technical indicators confirm Prothena Corporation plc’s reversalCommunity Picked Stocks with Trade Insights - Newser
How Prothena Corporation plc stock performs during market volatilityDay Trading Plan with Entry Risk Management - Newser
Prothena Secures Leadership with New Executive Agreements - TipRanks
Sector ETF performance correlation with Prothena Corporation plcMarket Entry and Exit Point Tips From Traders - metal.it
Is Prothena Corporation plc a Top Dividend Stock to Watch in 2025Market Entry and Exit Point Tips From Traders - metal.it
How to build a dashboard for Prothena Corporation plc stockTrading Volume Anomaly Summary and Insight - Newser
What makes Prothena Corporation plc stock price move sharplyIntelligent Trade Forecast With AI Analytics - Newser
Is There Enough Volume to Lift Prothena Corporation plcWeekly Top Gainers Forecast Watchlist Released - metal.it
Is it the right time to buy Prothena Corporation plc stockExpert Picks Forecasts Backed By Experts - jammulinksnews.com
Prothena Corporation plc Company Revenue and Profit Trends: A Deep DiveFree Fundamental + Technical Hybrid Stock Tips - Newser
Will Prothena Corporation plc see short term momentumFree Sector Rotation Based Trading Opportunities - Newser
Why Prothena Corporation plc stock attracts strong analyst attentionValue Holding Return Summary With Outlook - Newser
Bollinger Band Squeeze Points to Volatility in Prothena Corporation plcGrowth Based Investment Plan Guidance Highlighted - metal.it
Prothena to Report Second Quarter 2025 Financial Results on August 4 - BioSpace
Prothena Corporation plc Company Revenue and Profit Trends: A Deep Dive Free Buy Alerts With Low Risk Confirmation - metal.it
Is Prothena Corporation plc a growth stock or a value stockPre Market Planner For Beginners - jammulinksnews.com
How strong is Prothena Corporation plc company’s balance sheetUnlock powerful trading signals and alerts - jammulinksnews.com
How Prothena Corporation plc stock performs during market volatility Free Breakout Momentum Picks With Protection - Newser
What are Prothena Corporation plc company’s key revenue driversUnlock daily market insights for better decisions - jammulinksnews.com
How does Prothena Corporation plc generate profit in a changing economyMaximize returns with expert trading insights - jammulinksnews.com
What institutional investors are buying Prothena Corporation plc stockFree Predictions - jammulinksnews.com
New Product Launches: Will They Boost Prothena Corporation plc Stock in 2025Big Profit Small Risk Alerts - Newser
What is Prothena Corporation plc company’s growth strategyUnlock high-yield investment opportunities - jammulinksnews.com
What analysts say about Prothena Corporation plc stockFree Market Volatility Navigation Tips - PrintWeekIndia
Prothena Corporation plc Stock Analysis and ForecastDynamic investment opportunities - Autocar Professional
Is Prothena Corporation plc a good long term investmentHigh-yield investments - PrintWeekIndia
What drives Prothena Corporation plc stock priceFree Stock Market Real-Time Monitoring - PrintWeekIndia
Prothena Corporation plc (NASDAQ:PRTA) Receives $31.50 Average Price Target from Analysts - Defense World
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):